Pacira (PCRX) Biosciences announced it has joined the PROBE Consortium, a pioneering initiative to revolutionize osteoarthritis research and improve patient care and outcomes on a global scale .”Despite its prevalence, there continues to be significant unmet need in the treatment of OA due to the lack of innovation in therapeutic advancements since the launch of ZILRETTA in the U.S.,” said Frank Lee. “We are committed to advancing research and addressing the pressing needs of OA patients worldwide. As part of this commitment, we are proud to build on our established leadership by contributing valuable data to the PROBE initiative including findings from our ASCEND study, which is evaluating our investigational targeted gene therapy, PCRX-201, for the treatment of osteoarthritis.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira initiated with an Equal Weight at Barclays
- Pacira reports inducement grants under Nasdaq listing rule
- Pacira announces results from 12-month pilot study on iovera
- Pacira files patent infringement lawsuits against WhiteOak Group and Qilu
- Pacira Pharmaceuticals Faces Revenue Decline Amid Generic Competition and Patent Challenges, Analyst Issues Sell Rating